PODD stock sentiment todayInsulet Corporation
Sentiment verdict
Gossip first, financials second — NEUTRAL at 75% confidence.
Last updated · cached analysis, refreshes periodically
PODD
Insulet CorporationInsulet dominates the patch-pump niche with strong revenue growth, but GLP-1 fears and high valuation multiples create a volatile ceiling.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for PODD. Not financial advice.
Price · last 12 months
Gossip
The narrative is currently a tug-of-war between stellar Omnipod 5 adoption and the 'GLP-1 overhang'—investor fear that weight-loss drugs will reduce the total addressable market for insulin delivery.
- ·GLP-1 receptor agonist impact on long-term Type 2 insulin dependency
- ·Expansion into the Type 2 diabetes market (massive growth lever)
- ·Integration with G7 and Freestyle Libre sensors
Financial
Revenue growth remains robust (20%+), and the company has successfully transitioned to consistent GAAP profitability with expanding gross margins.
- ·Forward P/E: ~45x (High vs S&P, moderate vs med-tech peers)
- ·Revenue Growth: 23-25% YoY guidance
- ·Gross Margin: ~68-70%
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·Insiders bought a net $162K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Competitive entry into the patch-pump space (Medtronic/Tandem)
- ·Reduced insulin intensity in T2 patients due to weight-loss drugs
- ·High sensitivity to interest rate environments due to premium valuation
Peer temperature
How direct competitors stack up against PODD right now.
- HOTDXCMDexcom
HOTTER — lower clinical risk from GLP-1s as CGM usage is expanding into non-insulin users, providing a broader TAM than pumps.
See full analysis → - COLDTNDMTandem Diabetes Care
COLDER — struggling with negative earnings and slower growth as Insulet’s tubeless design wins market share from Tandem’s tubed systems.
See full analysis → - NEUTRALMDTMedtronic
COLDER GROWTH — trades at a significantly lower P/E with a solid dividend, but lacks the pure-play growth velocity of Insulet's Omnipod 5.
See full analysis →
- PODD+14.7%
- DXCM-4.6%
- TNDM+17.2%
- MDT+11.9%
Analyst price target
Consensus average of 21 analysts · median 175.00
Source: StockAnalysis.com · updated 2026-10-21
AI-generated analysis for informational purposes only. Not financial advice.